Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

NCT01361711 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT01361711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01361711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 30, 2011
Completion date
May 31, 2027
Enrollment
53 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

stage i chronic lymphocytic leukemia, stage ii chronic lymphocytic leukemia, stage iii chronic lymphocytic leukemia, stage iv chronic lymphocytic leukemia